Translational Lifestyle Medicine Approaches to Cardiovascular–Kidney–Metabolic Syndrome

Abstract

Highlights: What are the main findings? Cardiovascular–Kidney–Metabolic (CKM) syndrome arises from a complex interplay among heart, kidney, and metabolic dysfunction, worsened by factors like inflammation, oxidative stress, and insulin resistance. Lifestyle medicine interventions—focusing on nutrition, physical activity, stress management, sleep hygiene, social support, and avoidance of risky substances—can offer significant benefits in managing CKM-related risk factors such as high blood pressure, unhealthy lipid profiles, and poor glucose control, when implemented consistently. What are the implications of the main findings? Despite their potential benefits, lifestyle medicine strategies remain underutilized in clinical practice; integrating them as a core component of CKM prevention and management may meaningfully reduce risk burden. Future work and clinical pathways should emphasize personalized, integrative implementation (including digital health supports and sex-specific considerations) to address research gaps, reduce disparities, and optimize outcomes across diverse populations. Cardiovascular–Kidney–Metabolic (CKM) syndrome arises from interrelated cardiovascular, renal, and metabolic pathways that require coordinated therapeutic strategies. This narrative review synthesizes recent systematic reviews, meta-analyses, and original studies to evaluate the translational application of lifestyle medicine (LM) for CKM management. Evidence indicates that LM interventions targeting the six pillars of practice (nutrition, physical activity, stress management, sleep, social support, and avoidance of risky substances) can improve blood pressure, lipid profiles, glycemic control, and weight, with benefits that complement or at times rival pharmacotherapy. We outline opportunities at the LM–drug interface, including sodium-glucose cotransporter-2 inhibitors and nutrient-stimulated hormone agents such as GLP-1 and GIP, and highlight the need to test synergy and sequencing with LM. Persistent implementation barriers include prioritization of drug-centric care and limited protocolized delivery; the AHA 5A model and digital health tools, including wearables that enable real-time feedback, provide practical routes for integration. Marginalized populations carry a disproportionate burden of CKM, underscoring the need for equitable, culturally tailored approaches. Sex-specific gaps, particularly in post-menopausal lipid metabolism and insulin sensitivity, point to the promise of genomic and nutraceutical personalization. Future work should use preregistered, adequately powered multimodal trials to establish durable, scalable pathways for CKM care.